| Literature DB >> 31183513 |
Toshihiko Nishida1, Yasuo Okumura2,3, Katsuaki Yokoyama4, Naoya Matsumoto4, Eizo Tachibana5, Keiichiro Kuronuma5, Koji Oiwa1, Michiaki Matsumoto1, Toshiaki Kojima6, Shoji Hanada7, Kazumiki Nomoto8, Kazumasa Sonoda8, Ken Arima9, Rikitake Kogawa9, Fumiyuki Takahashi10, Tomobumi Kotani11, Kimie Ohkubo12, Seiji Fukushima13, Satoru Itou14, Kunio Kondo15, Masaaki Chiku16, Yasumi Ohno17, Motoyuki Onikura18, Atsushi Hirayama19.
Abstract
Direct-acting oral anticoagulants (DOACs) are widely used in aged Japanese patients with atrial fibrillation (AF), but outcome data for such patients are limited. We compared outcomes between 1895 (58.5%) patients aged < 75 years (non-elderly), 1078 (33.3%) 75-84 years (elderly) and 264 (8.2%) ≥ 85 years (very elderly) enrolled in a prospective multicenter registry. Kaplan-Meier analysis (median follow-up: 39.3 months) revealed a significantly high incidence of stroke/systemic embolism (SE) among the very elderly relative to that among the non-elderly or elderly (3.2 vs. 1.2 and 1.5 events per 100 patient-years, p < 0.001). Major bleeding in the non-elderly group was significantly infrequent relative to that among the elderly or very elderly group (1.1 vs. 1.6 vs. 1.8 events, p = 0.033). After multivariate adjustment, the stroke/SE incidence was comparable between DOAC and warfarin users, regardless of age, but major bleeding decreased significantly among very elderly DOAC users (adjusted HR 0.220, 95% CI 0.042-0.920). The greater increasing incidence of stroke/SE than major bleeding as patients age suggests that stroke prevention should outweigh the bleeding risk when anticoagulants are being considered for aged patients. Our data indicated that DOACs can be a therapeutic option for stroke prevention in very elderly patients.Entities:
Keywords: Aged; Atrial fibrillation; Direct oral anticoagulant; Warfarin
Mesh:
Substances:
Year: 2019 PMID: 31183513 DOI: 10.1007/s00380-019-01446-6
Source DB: PubMed Journal: Heart Vessels ISSN: 0910-8327 Impact factor: 2.037